The development of gene therapy approaches for connexin gene replacement in myelinating glial cells of the peripheral and central nervous systems is an important objective of the Neuroscience Department. Various delivery methods of lentiviral and AAV vectors harboring connexin genes are investigated in transgenic and knockout mouse models resulting in major pathological improvements. In addition, cell-targeted expression in myelinating glial cells of the peripheral and central nervous systems are explored through cell-specific and myelin-specific promoters, for a safer and more precise treatment.
